TNF Pharmaceuticals (TNFA) Competitors $0.06 -0.01 (-16.78%) Closing price 04:00 PM EasternExtended Trading$0.07 +0.01 (+10.24%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock TNFA vs. HCWB, KTTA, THAR, VYNE, BCTX, AEZS, SPRB, TTNP, CPHI, and REVBShould you be buying TNF Pharmaceuticals stock or one of its competitors? The main competitors of TNF Pharmaceuticals include HCW Biologics (HCWB), Pasithea Therapeutics (KTTA), Tharimmune (THAR), VYNE Therapeutics (VYNE), Briacell Therap (BCTX), Aeterna Zentaris (AEZS), Spruce Biosciences (SPRB), Titan Pharmaceuticals (TTNP), China Pharma (CPHI), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry. TNF Pharmaceuticals vs. Its Competitors HCW Biologics Pasithea Therapeutics Tharimmune VYNE Therapeutics Briacell Therap Aeterna Zentaris Spruce Biosciences Titan Pharmaceuticals China Pharma Revelation Biosciences TNF Pharmaceuticals (NASDAQ:TNFA) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Which has higher earnings and valuation, TNFA or HCWB? TNF Pharmaceuticals has higher earnings, but lower revenue than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTNF PharmaceuticalsN/AN/A-$23.36M-$2.31-0.03HCW Biologics$2.57M1.93-$30.02M-$14.04-0.25 Do analysts recommend TNFA or HCWB? HCW Biologics has a consensus price target of $35.00, indicating a potential upside of 914.49%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than TNF Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TNFA or HCWB? In the previous week, HCW Biologics had 4 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 7 mentions for HCW Biologics and 3 mentions for TNF Pharmaceuticals. TNF Pharmaceuticals' average media sentiment score of 0.78 beat HCW Biologics' score of -0.27 indicating that TNF Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TNF Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TNFA or HCWB? TNF Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Is TNFA or HCWB more profitable? TNF Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -1,368.55%. HCW Biologics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TNF PharmaceuticalsN/A -69.21% -33.98% HCW Biologics -1,368.55%N/A -40.72% Do institutionals & insiders believe in TNFA or HCWB? 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 42.7% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryTNF Pharmaceuticals beats HCW Biologics on 8 of the 15 factors compared between the two stocks. Get TNF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNFA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNFA vs. The Competition Export to ExcelMetricTNF PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$886K$2.80B$5.82B$9.74BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-0.0322.6131.1525.97Price / SalesN/A751.86475.57123.18Price / CashN/A173.2237.1558.38Price / Book0.175.869.116.39Net Income-$23.36M$31.83M$3.26B$265.66M7 Day PerformanceN/A1.80%2.11%1.98%1 Month PerformanceN/A4.36%5.12%1.33%1 Year PerformanceN/A11.44%31.25%21.15% TNF Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNFATNF PharmaceuticalsN/A$0.06-16.8%N/AN/A$886KN/A-0.036Earnings ReportGap DownHigh Trading VolumeHCWBHCW Biologics2.1845 of 5 stars$3.83-6.4%$35.00+814.1%-80.7%$5.49M$2.57M-0.1640Earnings ReportShort Interest ↑KTTAPasithea Therapeutics1.2416 of 5 stars$0.73+2.0%N/A-85.1%$5.39MN/A-0.103Positive NewsShort Interest ↓THARTharimmune3.3622 of 5 stars$1.26-3.1%$17.00+1,249.2%+74.4%$5.32MN/A-0.212News CoverageGap DownVYNEVYNE Therapeutics2.2175 of 5 stars$0.35+1.2%$6.25+1,696.0%-82.7%$5.29M$500K-0.3930BCTXBriacell Therap2.9453 of 5 stars$0.77+1.0%$32.00+4,050.5%-94.2%$5.14MN/A-0.098News CoverageAEZSAeterna ZentarisN/A$2.85-18.6%N/A-52.6%$5.11M$2.37M-0.1920High Trading VolumeSPRBSpruce Biosciences2.1582 of 5 stars$9.01+3.0%$131.25+1,356.7%-76.7%$5.06M$4.91M-9.5920Gap UpTTNPTitan Pharmaceuticals0.3168 of 5 stars$5.34+8.2%N/A-40.0%$4.72M$180K-1.7610CPHIChina Pharma0.9256 of 5 stars$1.44+1.0%N/A-92.7%$4.71M$4.30M0.00250Gap UpREVBRevelation Biosciences0.166 of 5 stars$2.77+2.2%N/A-97.5%$4.71MN/A-0.0410Short Interest ↑Gap Up Related Companies and Tools Related Companies HCW Biologics Alternatives Pasithea Therapeutics Alternatives Tharimmune Alternatives VYNE Therapeutics Alternatives Briacell Therap Alternatives Aeterna Zentaris Alternatives Spruce Biosciences Alternatives Titan Pharmaceuticals Alternatives China Pharma Alternatives Revelation Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNFA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.